Anti-CD34 antibody (Clone: 581) {APC}

Katalog-Nummer NB-22-61442-200

Size : 200Tests

Contact local distributor :


Telefonnummer : +1 850 650 7790

  • Human T lymphoblastic leukemia cell line Molt-4 were stained with Anti-CD34 antibody (filled gray histogram). Unstained Molt-4 (empty black histogram) were used as control.

General Info

Host: Mouse
Applications: FC
Reactivity: Human
Note: FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Hematopoietic progenitor cell antigen CD34 is suitable for use in Flow Cytometry research applications.
Clonality: Monoclonal
Clone ID: 581
Conjugation: APC
Isotype: IgG1k
Formulation: PBS with 0.05% Proclin300, 1% BSA
Storage Instruction: Recommend storing between 2-8°C and protecting from prolonged exposure to light. Do not freeze this product.

Information

Gene Symbol: CD34
Gene ID: 947
Uniprot ID: CD34_HUMAN

Description

Tissue Specificity Selectively expressed on hematopoietic progenitor cells and the small vessel endothelium of a variety of tissues.
Post Translational Modifications Highly glycosylated. Phosphorylated on serine residues by PKC.
Function Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins.
Protein Name Hematopoietic Progenitor Cell Antigen Cd34
Cd Antigen Cd34
Database Links Reactome: R-HSA-198933 P28906-1
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Hematopoietic Progenitor Cell Antigen Cd34 antibody
Anti-Cd Antigen Cd34 antibody
Anti-CD34 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance